Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by coculture with bone marrow stromal cells. by Wright, KT et al.
                             Elsevier Editorial System(tm) for The Spine Journal 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by co-culture with bone 
marrow stromal cells  
 
Article Type: Basic Science 
 
Section/Category: Basic Science/Physiology 
 
Keywords: Bone marrow stromal cells; Spinal motor neurites; Glial scar nerve inhibitors; Spinal cord 
injury 
 
Corresponding Author: Dr. Karina Wright,  
 
Corresponding Author's Institution: Keele University 
 
First Author: Karina Wright 
 
Order of Authors: Karina Wright; Kenzo Uchida; Jennifer Bara; Sally Roberts; Wagih El Masri; William 
Johnson 
 
Abstract: BACKGROUND CONTEXT: Transplantation of bone marrow cells into spinal cord lesions 
promotes functional recovery in animal models and recent clinical trials suggest possible recovery also 
in humans. The mechanisms responsible for these improvements are still unclear.  
PURPOSE: To characterise spinal cord motor neurite interactions with human bone marrow stromal 
cells (MSC) in an in vitro model of spinal cord injury (SCI).  
STUDY DESIGN/SETTING: Previously we have reported that human MSC promote the growth of 
extending sensory neurites from dorsal root ganglia (DRG), in the presence of some of the molecules 
present in the glial scar which are attributed with inhibiting axonal regeneration following SCI. We 
have adapted and optimized this system replacing the DRG with a spinal cord culture to produce a 
central nervous system (CNS) model which is more relevant to the SCI situation.  
METHODS: We have developed and characterised a novel spinal cord culture system. Human MSC were 
co-cultured with spinal motor neurites in substrate choice assays containing glial scar associated 
inhibitors of nerve growth. In separate experiments MSC conditioned media was analysed and added 
to spinal motor neurites in substrate choice assays.  
RESULTS: As has been reported previously with DRG, substrate-bound neurocan and Nogo-A repelled 
spinal neuronal body adhesion and neurite outgrowth, but these inhibitory effects were abrogated in 
MSC/ spinal cord co-cultures. However, unlike DRG, spinal neuronal bodies and neurites showed no 
inhibition to substrates of myelin associated glycoprotein. In addition, the MSC secretome contained 
numerous neurotrophic factors which stimulated spinal neurite outgrowth, but these were not 
sufficient stimuli to promote spinal neurite extension over inhibitory concentrations of neurocan or 
Nogo-A.  
CONCLUSIONS: These findings provide novel insight into how MSC transplantation may promote 
regeneration and functional recovery in animal models of SCI and in the clinic, especially in the chronic 
situation where glial scars (and associated neural inhibitors) are well established. In addition, we have 
confirmed that this CNS model predominantly comprises of motor neurons via immunocytochemical 
characterisation. We hope that this model may be used in future research to test various other 
potential interventions for spinal injury or disease states. 
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Abstract 3 
BACKGROUND CONTEXT: Transplantation of bone marrow cells into spinal 4 
cord lesions promotes functional recovery in animal models and recent clinical 5 
trials suggest possible recovery also in humans. The mechanisms responsible for 6 
these improvements are still unclear.  7 
PURPOSE: To characterise spinal cord motor neurite interactions with human 8 
bone marrow stromal cells (MSC) in an in vitro model of spinal cord injury (SCI).  9 
STUDY DESIGN/SETTING: Previously we have reported that human MSC 10 
promote the growth of extending sensory neurites from dorsal root ganglia 11 
(DRG), in the presence of some of the molecules present in the glial scar which 12 
are attributed with inhibiting axonal regeneration following SCI. We have adapted 13 
and optimized this system replacing the DRG with a spinal cord culture to 14 
produce a central nervous system (CNS) model which is more relevant to the SCI 15 
situation.  16 
METHODS: We have developed and characterised a novel spinal cord culture 17 
system. Human MSC were co-cultured with spinal motor neurites in substrate 18 
choice assays containing glial scar associated inhibitors of nerve growth. In 19 
separate experiments MSC conditioned media was analysed and added to spinal 20 
motor neurites in substrate choice assays.  21 
RESULTS: As has been reported previously with DRG, substrate-bound 22 
neurocan and Nogo-A repelled spinal neuronal body adhesion and neurite 23 
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outgrowth, but these inhibitory effects were abrogated in MSC/ spinal cord co-24 
cultures. However, unlike DRG, spinal neuronal bodies and neurites showed no 25 
inhibition to substrates of myelin associated glycoprotein. In addition, the MSC 26 
secretome contained numerous neurotrophic factors which stimulated spinal 27 
neurite outgrowth, but these were not sufficient stimuli to promote spinal neurite 28 
extension over inhibitory concentrations of neurocan or Nogo-A.  29 
CONCLUSIONS: These findings provide novel insight into how MSC 30 
transplantation may promote regeneration and functional recovery in animal 31 
models of SCI and in the clinic, especially in the chronic situation where glial 32 
scars (and associated neural inhibitors) are well established. In addition, we have 33 
confirmed that this CNS model predominantly comprises of motor neurons via 34 
immunocytochemical characterisation. We hope that this model may be used in 35 
future research to test various other potential interventions for spinal injury or 36 
disease states. 37 
38 
Introduction 39 
Injury to the central nervous system (CNS) usually initiates a poor intrinsic 40 
regenerative response for a number of reasons. Immune reactions, which in 41 
other tissues may help to recruit reparative cells, often have a devastating effect 42 
on CNS tissue function. Inflammation and ensuing secondary cascades can 43 
cause extensive neuronal and glial cell death, as well as glial cell activation and 44 
hypertrophy [1].  In an effort to restore the blood brain barrier, astrocytes at the 45 
site of injury become reactive and synthesise a proteoglycan rich matrix [2]. 46 
Myelin debris associated molecules, including Nogo-A and myelin associated 47 
glycoprotein (MAG), are also released from damaged neural tissues [3]. These 48 
events combine to produce a hostile environment for nerve re-growth [2-6].  49 
 There has been extensive interest world-wide in the development of cell 50 
transplantation strategies for the treatment of CNS damage, in particular spinal 51 
cord injury (SCI). Many diverse potential cell therapies have been tested, each 52 
targeting different distinct stages of SCI and mechanisms of spinal cord repair [7-53 
10]. Allogeneic embryonic stem cells (ES cells) and umbilical cord-derived cells, 54 
as well as possible autologous cell sources, including adult neural stem cells, 55 
Schwann cells and olfactory ensheathing cells have been shown to promote 56 
axonal regeneration and restore function in animal models of SCI [11-17]. These 57 
types of cell are thought to act in a number of ways depending on the cell type 58 
transplanted, including replacing dead or damaged neurons and glia, re-59 
establishing neural networks, remyelinating demyelinated axons and reducing the 60 
hostile nature of the SCI lesion.  61 
 Autologous cell therapies derived from bone marrow have also been 62 
shown to enhance functional recovery in animal models of SCI and possibly in 63 
the clinic [10], but the repair mechanisms responsible are still largely unclear. 64 
Some controversial evidence exists which suggests that bone marrow cells, 65 
including marrow stromal cell (MSC) and hematopoietic stem cell fractions, may 66 
trans-differentiate to replace lost neurons and glia, in a manner similar to that 67 
proposed for ES cells and neural stem cells [18-22]. However, the consensus of 68 
opinion seems to be that for MSC transplantation at least, the most likely mode of 69 
activity is an induction of a diverse myriad of paracrine anti-inflammatory 70 
pathways and directly restorative cell-matrix and cell-cell interactions [23-29]. 71 
 Previously we have used growth substrate choice assays to examine how 72 
human MSC influence neurite outgrowths from explants of chick dorsal root 73 
ganglia (DRG). We have demonstrated that MSC help neurites to overcome the 74 
effects of some of the major nerve inhibitory molecules found in SCI lesions, 75 
including neural proteoglycans, Nogo-A and MAG [30]. This established model of 76 
sensory nerve growth provided an excellent platform to examine in real-time 77 
possible cell-matrix and cell-cell interactions that may occur in the SCI milieu. In 78 
the current study, we have adapted and refined our system by replacing DRG 79 
explants with spinal cord cultures to provide a more relevant model of CNS nerve 80 
growth. We envisage that the establishment of a novel spinal nerve growth 81 
substrate assay, which comprises characterized motor neurons and relevant 82 
neural matrix molecules, will provide an invaluable research tool for testing SCI 83 
therapeutics, which will have further applications in the broader fields of CNS 84 
tissue engineering and repair. 85 
86 
Materials and methods 87 
Ethics Statement 88 
All research involving human participants was completed with written informed 89 
consent and Local Research Ethics Committee (LREC) approval: Shropshire & 90 
Staffordshire Strategic Health Authority, Reference Number: 04/02/RJH. Ethical 91 
approval and a Home Office project license for the study were not required under 92 
the United Kingdom Animal (Scientific Procedures) Act of 1986 because chicks 93 
were killed by decapitation (which is an appropriate method under Schedule 1 of 94 
the Act).  95 
Human bone marrow stromal cell (MSC) culture  96 
Bone marrow aspirates or bone chips were harvested from the iliac crest of 97 
individuals undergoing spinal fusion in the treatment for lumbar degenerative 98 
disorders (n=5; ages 29-53). Bone marrow aspirates and bone chips were kindly 99 
collected by spinal surgeons from the Centre for Spinal Disorders and sent to the 100 
Spinal Studies research laboratories for processing (both based at the RJAH 101 
Orthopaedic Hospital, Oswestry, UK). 102 
 Bone chips were perfused with Dulbecco’s Modified Eagle’s Medium 103 
(DMEM/F12), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin 104 
and streptomycin (P/S) (Invitrogen Life Technologies, Paisley, UK). Mononuclear 105 
cells isolated by density gradient centrifugation at 900g for 20 minutes over 106 
Lymphoprep™ (Fresenius Kabi Norge, AS) were plated out in DMEM/ 20% FBS 107 
+ P/S medium (Invitrogen Life Technologies) at a seeding density of 20 x 106 108 
cells per flask. After 24 hours, non-adherent cells were removed and the 109 
adherent cell populations were cultured in monolayer and were maintained in a 110 
humidified atmosphere of 5% CO2 at 37
0C through to passage II-III in DMEM/ 111 
10% FBS + P/S medium. MSC cultures used in this study were characterised 112 
according to the MSC CD immunoprofile criteria published by the International 113 
Society for Cellular Therapy [31]. 114 
Embryonic chick neuronal cultures  115 
Spinal cords were dissected from E4.5 hybrid brown chicks as described 116 
previously [32] and cut into 10-20 pieces per cord, such that all were of 117 
approximately equal size. These were then digested in 20l of trypsin (2.5% w/v; 118 
final concentration 0.05%) in PBS (Invitrogen Life Technologies) for 15 minutes 119 
at 370C whilst agitating frequently. The trypsin supernatant was removed and 120 
replaced by 900l of neuronal culture medium (NCM; L-15 culture medium 121 
supplemented with 1% (v/v) insulin, transferrin and selenium, 1% (v/v) P/S (L-15/ 122 
ITS-X/ P/S medium, Invitrogen Life Technologies), 1% (v/v) horse serum and 123 
1.5mg/ml glucose) (Sigma-Aldrich, Poole, UK) and 100l of 4% (w/v) bovine 124 
serum albumin (BSA; Sigma-Aldrich). The spinal cord tissue was homogenized 125 
using a pipette and spinal cord neuronal cells were isolated by density gradient 126 
centrifugation at 500g for 15 minutes over a warmed 1.5ml cushion of 6.8% (v/v) 127 
Nycodenz® (Serva, Heidleberg, Germany). Dissociated cells were seeded into 128 
24-well tissue culture plates (Co-star, Corning Inc, NY) pre-coated with nerve- 129 
permissive and nerve-inhibitory molecules (see below) in NCM supplemented 130 
with 0.4% (v/v) N2-supplement and 10ng/ml basic fibroblast growth factor (bFGF) 131 
(Invitrogen Life Technologies) at a seeding density of 3 x 105 cells per well and 132 
were maintained in a humidified atmosphere of 5% CO2 at 37
0C for 72 hours. 133 
Optimisation of chick neuronal culture growth substrata  134 
Briefly, some wells were pre-coated with a thin layer of protein-binding 135 
nitrocellulose (BA85, Schleicher & Schuell, Dassel, Germany). Pre-coated and 136 
uncoated plates were then further incubated with either PBS or 25μg/ml laminin 137 
(derived from Engelbreth-Holm-Swarm mouse tumour, BD Biosciences, Oxford, 138 
UK) in PBS. After coating, all wells were washed repeatedly with PBS prior to 139 
seeding with neuronal cultures.  Control DRG plates for SC1 immunostaining 140 
were established using embryonic chick day 10 DRG as described previously 141 
[30]. 142 
MSC/ neuronal co-cultures  143 
MSC were labelled with Cell TrackerTM Red Fluorescent Probe (Cambrex 144 
Bioscience, Wokingham, UK) following the manufacturer’s protocol.  Labelled 145 
cells were seeded (at a density of 5 x 103 cells/ cm2) in DMEM/ 10% FBS + P/S 146 
into plates coated with nerve-permissive and nerve-inhibitory substrata (see 147 
below). After 24 hours, any non-adherent cells were removed and wells washed 148 
repeatedly before adding N2 and bFGF-supplemented NCM. Neuronal cultures 149 
were then immediately seeded into each well and the MSC/ neuronal co-cultures 150 
maintained in a humidified atmosphere of 5% CO2 at 37
0C for 72 hours. Control 151 
plates of neuronal cultures seeded alone, i.e., without pre-seeded MSC, were 152 
established at the same time in N2 and bFGF-supplemented NCM. 153 
Mixed substrate preparation  154 
Neurocan, isolated from embryonic chick brains and purified with a monoclonal 155 
antibody (Millipore, Billerica, MA), was used to coat tissue culture plates in 156 
restricted localities, as described previously [30, 33,34]. Briefly, wells were pre-157 
coated with a thin layer of protein-binding nitrocellulose (see above), which was 158 
then blotted with 350μm wide strips of filter paper (Whatman No.1, GE 159 
Healthcare, Maidstone, Kent, UK) that had been soaked in neurocan at 160 
concentrations ranging from 1μg-50μg/ml (in PBS). After the filter strips had dried 161 
and been removed, the plates were then washed with PBS. The restricted 162 
localisation of the neurocan on the culture plates was visualized by inclusion of a 163 
marker dye (5% v/v rhodamine B, Sigma-Aldrich) in the neurocan solution. The 164 
same technique was used to prepare culture plates with substrates of 10-165 
400μg/ml recombinant Nogo-A on nitrocellulose or 10-400μg/ml recombinant 166 
MAG on nitrocellulose (both R&D Systems, Abbingdon, UK). After coating, all 167 
wells were washed repeatedly with PBS prior to seeding with neuronal cultures 168 
and/ or MSC. 169 
SC1 and neurofilament (NF) 200kD immunostaining  170 
SC1 is a cell surface adhesion molecule expressed on motor neuron cell bodies 171 
and axons [35], which can be used to purify motor neurons from spinal cord 172 
tissues [36]. Neuronal cell cultures were immunolabelled with SC1 for motor 173 
neuron characterisation, whereas NF immunolabelling was used for neurite 174 
quantitation because the NF immunofluorescence was much stronger and hence 175 
better for the counting of fine neurite extensions. 176 
 Neuronal cell cultures were fixed by gently adding an equal volume of 4% 177 
(w/v) buffered paraformaldehyde (BDH Biosciences) to the culture medium in 178 
each well for 10 minutes. Wells were washed with PBS twice for 10 minutes. 179 
Cells were then incubated for 1 hour with a blocking buffer of 10% goat serum 180 
(Vector Laboratories, Burlingame, CA) in PBS at room temperature. Mouse 181 
monoclonal anti-SC1 (neat) (kindly donated by Prof Hideaki Tanaka, Kumamoto 182 
University, Japan) or anti-NF (1:200) (clone NE14, Sigma-Aldrich) were used as 183 
the primary antibodies, and goat anti-mouse Alexa Fluor 488 (1:100) (Invitrogen 184 
Life Technologies) was used as a secondary antibody. Cells were incubated with 185 
the primary antibody for 1 hour and the secondary antibody for 40 minutes at 186 
room temperature to stain neuronal bodies and their neurites fluorescent green. 187 
Fibronectin and laminin immunostaining 188 
 MSC cultures were fixed by gently adding an equal volume of 4% (w/v) buffered 189 
paraformaldehyde to the culture medium in each well for 10 minutes. Wells were 190 
washed with PBS twice for 10 minutes. Cells were then incubated for 20 minutes 191 
with a blocking buffer of 15% horse serum (Vector Laboratories) in PBS at room 192 
temperature. Rabbit polyclonal anti-fibronectin (250g/ml) or anti-laminin 193 
(25g/ml) (both, Sigma-Aldrich) were used as the primary antibodies, and 194 
biotinylated goat anti-rabbit (50g/ml, Vector Labs) was used as a secondary 195 
antibody followed by a fluorescein-streptavidin complex (20g/ml, Vector Labs). 196 
Cells were incubated with the primary antibody overnight, the secondary antibody 197 
for 40 minutes and the fluorescein-streptavidin complex for 20 minutes at room 198 
temperature. 199 
MSC-CM neuronal culture assays 200 
MSC-CM (n=6) were generated as described previously [30] and stored at -20oC 201 
prior to use. Neuronal cell cultures were seeded in MSC-CM in culture plates that 202 
had either been uniformly coated in nitrocellulose or coated with nitrocellulose 203 
and  strips of neurocan (50g/ml) or Nogo-A (400g/ml), as described above. 204 
Control neuronal cultures were maintained in non-conditioned media under the 205 
same conditions. Neurite outgrowth was measured after 72 hours in culture. 206 
MSC-CM neurotrophic protein arrays 207 
MSC-CM were screened for a panel of 23 neurotrophic proteins using custom 208 
designed antibody arrays (RayBiotech Inc, Norcross, GA) according to the 209 
manufacturer's instructions. In brief, array membranes with protein antibodies 210 
spotted in duplicate were incubated with blocking buffer for 30 minutes at room 211 
temperature. MSC-CM were thawed and incubated with the membranes 212 
overnight at 4°C. Membranes were washed and then incubated with a Biotin-213 
conjugated antibody for 1 hour. Wash steps were repeated as before and 214 
membranes incubated with HRP-conjugated streptavidin for 2 hours. Following 215 
another series of wash steps, membranes were incubated with a 216 
chemiluminescent detection reagent provided in the kit for 2 minutes. Positive 217 
signals were visualised with a chemiluminescence imaging system (ChemiDoc™ 218 
EQ, Bio-Rad Laboratories Srl, Italy). Array data was semi-quantified by 219 
measuring the sum of the intensities of the pixels within each spot boundary x 220 
pixel area, with image analysis software (Quantity One® version 4.6.3, Bio-Rad, 221 
Italy). A signal from a clear part of the array was subtracted from all data to 222 
account for background signal. A mean was taken from the two duplicate spots 223 
for each factor. Levels of neurotrophic factors were normalised to positive 224 
controls (provided in the kit) and to the number of MSC that had generated a 225 
standard volume of conditioned media. 226 
Microscopy, image capture and analysis 227 
Cultures were viewed using phase contrast and fluorescence microscopy (Nikon 228 
Eclipse TS100, Nikon, Kingston-upon-Thames, UK). Digitized images were 229 
captured with a black and white Hamamatsu digital camera (C4742-95) and 230 
examined using IPLab software (Version 3.6, Nikon). For determination of the 231 
optimal substrate for growth of embryonic chick spinal neuronal cultures, cell 232 
aggregates and neuronal body adhesion, and neurite outgrowth were counted 233 
using phase contrast and fluorescence images. A cell aggregate was determined 234 
as a cluster of more than one adhered cell visible under phase microscopy. NF 235 
immunolabelling, visible under fluorescence microscopy was used to stain 236 
neurites and to determine those cell aggregates that were of a neuronal 237 
phenotype. Hence, those cell aggregates that were immunopositive for NF and 238 
possessed neurites (that is, if a neurite ≥25m in length were in contact with a 239 
neuronal body) were then described as ‘neuronal bodies’.  For substrate choice 240 
assays, the number of neuronal bodies with neurites that had adhered onto 241 
substrates of plastic, nitrocellulose, laminin, neurocan, Nogo-A or MAG were 242 
quantified using fluorescent images. For all analysis, adhered neuronal bodies 243 
with neurites were counted after 72 hours in culture. The number of red 244 
fluorescent MSC that were present on the nitrocellulose, neurocan, Nogo-A or 245 
MAG substrates in each digitized image was also scored. For substrate choice 246 
assay quantitation, results from at least 5 separate cultures and 5 separate 247 
images per culture were pooled and combined. 248 
 MSC-CM neurite outgrowth assays were viewed and quantified using 249 
phase contrast microscopy and digitized images captured and examined using 250 
the Cell IQ® Imagen system and Analyser software (Chip-Man Technologies, 251 
Tampere, Finland). In brief, phase contrast images of cultures (n=12 controls and 252 
n=24 MSC-CM) were captured using a fully automated system every 2-3h over a 253 
period of 72 hours. From these images, the Cell-IQ® Analyser software 254 
automated search tool ‘neurite finder’ generated temporal neurite length data for 255 
each culture condition. 256 
Statistical analysis  257 
The Mann-Whitney U test was used to assess significant differences: (i) between 258 
the frequency of neuronal bodies adhered with extending neurites onto uniform 259 
substrates of plastic, nitrocellulose and laminin, (ii) between the frequency of 260 
neuronal bodies adhered with extending neurites onto each of the adjacent 261 
substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A 262 
or MAG in neuronal and MSC co-cultures, compared to control neuronal cultures 263 
alone, (iii) between the frequency of MSC adhered onto each of the adjacent 264 
substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A 265 
or MAG. The relationship between the relative amounts of each neurotrophic 266 
protein and the total neurite outgrowth in each MSC-CM was determined using 267 
the Spearman ranked correlation coefficient rs. 268 
Results 269 
Nitrocellulose substrates promote optimal growth of embryonic chick spinal 270 
neuronal cultures. 271 
Embryonic chick spinal cells formed aggregates which adhered to both plastic 272 
and nitrocellulose substrates with or without laminin coating to varying degrees 273 
(Fig 1A). A number of fibroblastic cells adhered to substrates of plastic alone; a 274 
small proportion of these cells extended neurites but these were difficult to 275 
distinguish from neighbouring aggregates in close proximately. Cells seeded onto 276 
substrates of plastic coated with laminin or nitrocellulose formed discrete cell 277 
aggregates and the majority of these aggregates possessed neurites. The 278 
frequency of neurites was increased on substrates of plastic coated with 279 
nitrocellulose compared to plastic (with or without laminin) (Fig 1B). For 280 
substrates of nitrocellulose coated plastic with laminin, fibroblastic cell 281 
aggregates were so confluent they could not be reliably separated for 282 
quantitation. 283 
 Embryonic chick spinal cell aggregates and neurites were then fixed and 284 
immunostained for neurofilament (NF) (Fig 1C). A large proportion of those cell 285 
aggregates which had adhered to plastic alone were lost following fixation and 286 
immunostaining. The discrete cell aggregates which had adhered to the laminin 287 
or nitrocellulose coated plastic were identified as NF immunoreactive neuronal 288 
bodies. In addition, the extended cell processes that were seen emanating from 289 
these cell aggregates were identified as NF immunoreactive neurites. The 290 
frequency of neurites was increased on substrates of nitrocellulose coated plastic 291 
compared to plastic (with or without laminin) (Fig 1D). For substrates of 292 
nitrocellulose coated plastic with laminin, there was no clear aggregation of NF 293 
immunoreactive cells to form discrete neuronal bodies, with a confluence of cells 294 
growing across the substrate instead; hence the distribution of discrete NF 295 
immunoreactive neuronal bodies could not be measured. 296 
Embryonic chick spinal neuronal cultures are immunopositive for the motor 297 
neuron marker SC1 298 
Embryonic chick dorsal root ganglion (DRG) cultures were negative for SC1 299 
immunocytochemical staining as were isotype matched control wells (Figs 2A 300 
and 2B). In contrast, a large proportion of spinal neuronal cultures were 301 
immunopositive for SC1 (with corresponding negative staining of isotype 302 
matched control wells) (Figs 2C-E). 303 
Embryonic chick spinal neuronal cultures are inhibited by neurocan and Nogo-A 304 
but not MAG 305 
Neuronal bodies with neurites were repelled by neurocan and Nogo-A in a 306 
concentration-dependent manner (Fig 3A and 3B). At high neurocan and Nogo-A 307 
concentrations (50μg/ml and 400g/ml respectively), neuronal body adhesion 308 
and neurite outgrowth was almost completely inhibited (<1 neuronal body with at 309 
least one neurite per image). At lower neurocan and Nogo-A concentrations (1-310 
10μg/ml and 10-200μg/ml respectively), increasing numbers of neuronal bodies 311 
and neurites adhered to neurocan and Nogo-A substrates and extended neurites. 312 
In contrast, neuronal cultures seeded onto nitrocellulose: MAG substrate assays 313 
showed no preference for either substrate, i.e. neuronal bodies and neurites were 314 
not inhibited by MAG at any concentration (5-400g/ml) (Fig 3C). No evidence of 315 
neuronal cell death (as delineated by cell detachment) was observed in any of 316 
the cultures tested. 317 
MSC promote embryonic chick spinal neuronal adhesion and neurite extension 318 
over substrata of neurocan, Nogo-A and MAG 319 
In MSC/ neuronal co-cultures, neuronal bodies were able to adhere and extend 320 
neurites over high neurocan and Nogo-A concentrations, such that ~5 neuronal 321 
bodies with neurites per image were present on 50μg/ml neurocan and ~3 322 
neuronal bodies with neurites per image were present on 400g/ml Nogo-A. 323 
However, the inhibitory effects of neurocan and Nogo-A on neuronal adhesion 324 
and neurite outgrowth were only partially abrogated when compared to 325 
substrates of nitrocellulose. Some of the pre-seeded MSC appeared to align at 326 
the borders of nitrocellulose with neurocan or Nogo-A, suggesting that these cells 327 
were also inhibited by the nerve-inhibitory matrix molecules. Nonetheless, it was 328 
apparent that even at high neurocan and Nogo-A concentrations, some MSC 329 
were still able to adhere to the neurocan and Nogo-A substrates and it was to 330 
these MSC that the adherent neuronal bodies and neurites were often co-331 
localised (Figs 4A and 4B). MSC, neuronal bodies and neurites were not inhibited 332 
by MAG at any concentration (5-400g/ml) (Fig 4C). Nonetheless, neuronal body 333 
adhesion and neurite extension was increased on all substrates, including 334 
neurocan, Nogo-A, MAG and nitrocellulose when in co-culture with MSC in 335 
comparison to the absence of MSC. In addition, MSC traversing inhibitory 336 
substrata were immunopositive for the nerve permissive matrix molecules laminin 337 
and fibronectin (Fig 4D). 338 
MSC conditioned media (MSC-CM) promotes spinal neurite outgrowth over 339 
nitrocellulose but not neurocan or Nogo-A inhibitory substrata 340 
MSC-CM significantly increased spinal neurite extension over nitrocellulose 341 
substrates compared to control cultures in non-conditioned media (Fig 5A). We 342 
have detected several neurotrophic proteins in MSC-CM which may be important 343 
in stimulating spinal neurite outgrowth (Fig 5B). Of the neurotrophic factors 344 
identified, the levels of granulocyte colony stimulating factor (GCSF), fibroblast 345 
growth factor-4 (FGF-4) and matrix metalloproteinase-8 (MMP-8) correlated 346 
significantly to the quantity of neurite outgrowth detected (Spearman Rank rs 347 
0.57, p=*0.014, rs 0.57, p=***<0.0001 and rs 0.66, p=**0.0032 respectively). 348 
However, MSC-CM alone was not sufficient stimulus to promote neurite 349 
outgrowth over inhibitory concentrations of neurocan or Nogo-A (Fig 5C).350 
Discussion 351 
MSC transplantation for the treatment of SCI has proven efficacious in terms of 352 
promoting axonal regeneration and functional recovery in animal models and 353 
possibly in the clinic [10]. However, few definitive experiments have addressed 354 
the mechanisms involved in this process. We have developed a substrate choice 355 
assay to examine how spinal nerves interact in co-culture with MSC, specifically 356 
in the context of molecules that are present at the site of SCI and that are 357 
considered to form major inhibitors to axonal regeneration. Using this model we 358 
have shown that spinal neuronal bodies and neurites are inhibited by neurocan 359 
and Nogo-A in a concentration dependent manner, akin to DRG sensory 360 
neurites, which we have reported previously [30]. Increased concentrations of 361 
these extracellular inhibitors, however, were required to observe a similarly 362 
‘complete’ inhibition, e.g. 50g/ml of neurocan and 400g/ml Nogo-A completely 363 
inhibited spinal neurites, compared to 10g/ml of neural proteoglycans (which 364 
includes neurocan) and 200g/ml Nogo-A for the complete inhibition of DRG 365 
neurite outgrowth. However, unlike DRG sensory neurites, spinal cultures were 366 
not inhibited by MAG substrates at any of the concentrations tested (up to 367 
400g/ml). Hence, using this CNS system we have shown that one of the 368 
proposed inhibitors in the glial scar (MAG) may not be as potent in CNS systems 369 
as it is in DRG systems, which may have important implications for our 370 
understanding of nerve growth inhibition in the SCI setting. There is some 371 
supportive evidence in the literature for these findings which suggest that MAG 372 
may not be a crucial inhibitor of axonal regeneration in the CNS. For example, 373 
Bartsch et al. [37] have shown that MAG deficient mice exhibit poor axonal 374 
regrowth following either optic nerve or corticospinal tract transection in vivo, 375 
although MAG has been shown by others to repel both peripheral nervous 376 
system (PNS) and CNS nerve growth [30, 38, 39]. 377 
 There are a number of distinctions between these neuronal cultures which 378 
might account for the differences we have observed in their response to 379 
substrate choice assays, compared to those results previously reported. The 380 
most obvious is the developmental stage of each tissue source; in the current 381 
study, spinal cultures were isolated 4.5 days after fertilization, compared to our 382 
previous work using DRG explants from day 10 embryos [30]. The expression of 383 
axonal guidance ligands and receptors, including myelin receptors are known to 384 
change throughout CNS and PNS development [40-44], which may explain why 385 
spinal and DRG cultures exhibit different sensitivities to MAG. In addition, both 386 
our current and previous methods of primary neuronal culture isolation included 387 
few (if any) purification steps and hence, these cultures are composed of mixed 388 
cell populations. We are in the process of characterising those ‘fibroblast-like’ 389 
cells visible in CNS and PNS cultures, which are likely to have influenced the 390 
sensitivity of neuronal cultures in substrate ‘choice’ assays. There is a possibility 391 
that other CNS cell types may have reduced the sensitivity of spinal neurites to 392 
MAG substrates, perhaps by physically masking or blocking inhibitory epitopes, 393 
or by secreting growth factors that blocked the inhibitory effects of MAG, e.g. 394 
brain derived neurotrophic factor (BDNF) [45]. In contrast, Schwann cells, which 395 
may be present in mixed PNS cultures, could exacerbate sensory nerve reactivity 396 
to MAG via an additive effect, as Schwann cells themselves express nerve 397 
inhibitory MAG [46]. Furthermore, each culture environment varies greatly in 398 
media composition and growth factor supplementation which may also impact 399 
directly on the sensitivity of neurites to inhibitory substrates, including MAG [45, 400 
47]. For example, the exposure to neurotrophins has been shown to upregulate 401 
chimaerin (one of the Rho-GTPase activating proteins) in cerebellar neurons [48]. 402 
The expression of chimaerin in the cerebellum is correlated with abolishment of 403 
the inhibitory effects of MAG in development and ectopic expression of chimaerin 404 
in cerebellar neurons in vitro results in resistance to MAG induced neurite 405 
inhibition [48]. 406 
 We have demonstrated that MSC co-culture reduces the inhibitory effects 407 
of neurocan and Nogo-A on spinal neuronal body adhesion and neurite 408 
outgrowth and enhances spinal neurite outgrowth over all of the substrates tested 409 
(neurocan, Nogo-A, MAG and nitrocellulose). We have also shown that MSC 410 
were repelled by high concentrations of neurocan and Nogo-A (but not MAG 411 
substrates). Hence, at high concentrations MSC could clearly be seen to align 412 
along inhibitory neurocan and Nogo-A borders. Although MSC were inhibited to a 413 
much lesser extent than spinal neuronal bodies and their associated neurites. 414 
This is not too surprising as we already know that MSC may have an increased 415 
capacity to adhere to and migrate over neural proteoglycans, Nogo-A and MAG 416 
compared to other cell types [30]. The exact mechanisms responsible for the 417 
abrogation of spinal nerve inhibition to neurocan and Nogo-A in MSC co-cultures 418 
may involve a number of complex paracrine, cell-matrix and cell contact-419 
mediated interactions. We and others have previously reported that MSC-CM 420 
promotes neurite outgrowth from DRG explants and that and that MSC 421 
synthesise a number of soluble cytokines and other growth factors that are 422 
known to stimulate nerve extension including NGF, BDNF and vascular 423 
endothelial growth factor [26, 30, 49]. In this study we have shown that MSC-CM 424 
promotes spinal neurite outgrowth and contains several neurotrophic proteins, 425 
including GCSF, FGF-4 and MMP-8 which significantly correlated to the level of 426 
spinal neurite stimulation observed. However, we show that MSC-CM alone was 427 
insufficient stimuli to promote spinal neurite extension over inhibitory 428 
concentrations of neurocan or Nogo-A. 429 
 There are other explanations which might account for spinal neurites 430 
extending over inhibitory substrates in MSC co-cultures. MSC are known to 431 
synthesise numerous extracellular matrices that support neuronal cells and 432 
provide an optimal surface for nerve growth [50]. We have shown using our 433 
model that migrating MSC provide permissive matrix ‘bridges’ of laminin and 434 
fibronectin over nerve inhibitory substrates. In addition, in many sequences and 435 
on all inhibitory substrata tested, MSC and spinal neurites co-localised. Whereby 436 
MSC appeared to act as adhesive ‘stepping stones’ for neurite extension. 437 
Alternatively, nerve-inhibitory molecules, particularly neural proteoglycans such 438 
as neurocan, may have been degraded by matrix metalloproteinases (MMPs), 439 
e.g. MMP-1, MMP-2, MMP-13, which MSC are known to synthesise [51]. We 440 
have previously demonstrated that cell contact-mediated events, such as towing 441 
of neurites and bridging of inhibitory substrata, may play an important role in 442 
MSC abrogating the DRG nerve-inhibitory effects of neural proteoglycans, Nogo-443 
A and MAG [30]. Further experimentation using this system will aim to elucidate 444 
which of these mechanisms contribute to MSC stimulation of spinal neurite 445 
outgrowth over neurocan and Nogo-A, and to what extent. This may help to 446 
identify molecular targets to further enhance nerve growth in SCI environments. 447 
 There are few primary motor neuron culture protocols available for 448 
scientists to examine new therapies for CNS repair, particularly in the context of 449 
the injured spinal cord. We have modified an existing protocol [32] to test 450 
embryonic motor neurons, as characterised by SC1 staining, cultured on 451 
substrate choice assays. We suggest that the development of this assay and its 452 
refinement for the testing of adult spinal motor neurite outgrowth over different 453 
growth surfaces will provide a valuable tool to examine motor neuron and glial 454 
cell-matrix and cell-cell interactions, not readily achieved when using complex in 455 
vivo models. We anticipate that this novel system may help to further elucidate 456 
some of the mechanisms of increased axonal regeneration that has been noted 457 
following MSC transplantation for the treatment of SCI, as well as having wider 458 
application in  the field of spinal therapeutics. 459 
460 
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Figure Legends 630 
Figure 1. Nitrocellulose promotes optimal growth of embryonic chick spinal 631 
neuronal cultures. A: Spinal cord cells formed many small fibroblastic aggregates 632 
with few neurites on plastic alone, larger cell aggregates with some neurites were 633 
formed on plastic pre-coated with laminin. Similar large cell aggregates were 634 
formed on nitrocellulose alone but with many more associated neurites. Cells 635 
seeded onto nitrocellulose pre-coated with laminin formed an almost confluent 636 
fibroblastic culture with few neurites. Examples of neurites are indicated by black 637 
arrows. Digitized images under phase contrast microscopy (calibration bar = 638 
100m). B: The number of cell aggregates with neurites was significantly 639 
increased on nitrocellulose substrates alone compared to plastic (with or without 640 
laminin) (*p=0.0042 and *p=0.0062 respectively, Mann Whitney U test: data 641 
shown are from at least 5 separate cultures and 5 separate images per culture 642 
combined ± SEM). C: Most cell aggregates on plastic substrates were lost 643 
following fixation and immunostaining, some neurofilament staining of neuronal 644 
bodies and neurites was observed on plastic pre-coated with laminin. On 645 
nitrocellulose alone many neuronal bodies were immunopostive for neurofilament 646 
as were a complex network of associated neurites. The nuclei of cells seeded 647 
onto nitrocellulose pre-coated with laminin were stained but few neurites were 648 
visible. Digitized images under fluorescence microscopy (calibration bar = 649 
100m). D: After immunostaining for neurofilament the number of neuronal 650 
bodies with neurites was significantly increased on nitrocellulose substrates 651 
alone compared to plastic (with or without laminin) (*p=0.0034 and *p=0.0067 652 
respectively, Mann Whitney U test: data shown are from at least 5 separate 653 
cultures and 5 separate images per culture combined ± SEM). 654 
Figure 2. Embryonic chick spinal neuronal cultures are immunopositive for SC1, 655 
a motor neuron marker. A-E: Representative digitized images of identical fields 656 
are shown from left to right. Left panels show phase images and right panels 657 
show immunolocalisation for SC1 (A and C) and isotype matched controls (B and 658 
D). A and B are DRG explants (negative for SC1 staining), C and D are spinal 659 
neuronal cultures (positive for SC1 staining). E: At low magnification 660 
encompassing a wide field of view, many if not all neuronal bodies and neurite 661 
networks in spinal neuronal cultures were immunopositive for SC1. Calibration 662 
bars = 100m. 663 
Figure 3. Neurocan, Nogo-A and MAG spinal neuronal body adhesion and 664 
neurite outgrowth assays. A-C Digitized images of identical fields are shown from 665 
left to right under phase contrast and fluorescence microscopy (middle panels 666 
illustrate the location of the neurocan, Nogo-A or MAG, right panels show NF 667 
immunolabelled neuronal bodies and neurites, calibration bars = 100m).  A: 668 
Neurocan substrates repelled neuronal body adhesion and neurite outgrowth in a 669 
dose dependant manner. The difference in the frequency of neuronal bodies with 670 
neurites which had adhered to neurocan substrates compared to nitrocellulose 671 
was significant at concentrations of 1, 5, 10 and 50g/ml (**p=0.059 and 672 
***p<0.0001 Mann Whitney U test). B: Nogo-A substrates repelled neuronal body 673 
adhesion and neurite outgrowth in a dose dependant manner. The difference in 674 
the frequency of neuronal bodies with neurites which had adhered to Nogo-A 675 
substrates compared to nitrocellulose was significant at concentrations of 50, 676 
100, 200 and 400g/ml (***p<0.0001 Mann Whitney U test). C: There was no 677 
difference in the frequency of neuronal bodies with neurites which had adhered to 678 
MAG substrates compared to nitrocellulose at any of the concentrations tested 679 
(10, 50, 100, 200 or 400g/ml). Data shown are from at least 5 separate cultures 680 
and 5 separate images per culture combined +/-SEM.  681 
Figure 4. In MSC co-cultures, the inhibitory effects of neurocan and Nogo-A 682 
substrates on neuronal body adhesion and neurite outgrowth were reduced. MSC 683 
co-cultures also enhanced neuronal body adhesion and neurite outgrowth over 684 
MAG. A-C: Digitized images of identical fields are shown from left to right under 685 
phase contrast and fluorescence microscopy (middle panels illustrate the location 686 
of the neurocan, Nogo-A or MAG and fluorescently labelled MSC, right panels 687 
show NF immunolabelled neuronal bodies and neurites, calibration bars = 688 
100m).  A: MSC adhesion was reduced on high concentrations of neurocan (10 689 
and 50g/ml) compared to nitrocellulose (*p=0.0217 and ***p<0.0001 Mann 690 
Whitney U test). Neuronal body adhesion and neurite extension was only 691 
inhibited at the highest concentration of neurocan (50g/ml) in MSC co-cultures 692 
(***p<0.0001 Mann Whitney U test). B: MSC adhesion was reduced on 400g/ml 693 
Nogo-A substrates compared to nitrocellulose (***p<0.0001 Mann Whitney U 694 
test). Neuronal body adhesion and neurite extension was only inhibited at the 695 
highest concentration of Nogo-A (400g/ml) in MSC co-cultures (***p<0.0001 696 
Mann Whitney U test). C: There was no difference in the frequency of MSC or 697 
neuronal bodies with neurites which had adhered to MAG substrates compared 698 
to nitrocellulose at any of the concentrations tested (10, 50, 100, 200 or 699 
400g/ml). Black arrows indicate co-localisation of MSC and spinal neurites, 700 
white arrows indicate independent binding of neurites to inhibitory substrates. 701 
Data shown are from at least 5 separate cultures and 5 separate images per 702 
culture combined +/-SEM. D: MSC shown bridging nerve inhibitory substrata 703 
were immunopositive for laminin and fibronectin. 704 
Figure 5. MSC conditioned media (MSC-CM) stimulates spinal neurite outgrowth, 705 
but not over inhibitory neurocan or Nogo-A substrata. A: Representative digitized 706 
images of neurite outgrowth over nitrocellulose in control media (top panel) and 707 
MSC-CM (bottom panel) under phase contrast microscopy are shown with 708 
digitized CellIQ® ‘neurite finder’ overlays, calibration bars = 100m. Analysing 709 
pooled data (n=6 MSC-CM) demonstrated a marked and significant increase in 710 
neurite length following culture in MSC-CM compared to control medium 711 
(*p<0.0384 Mann Whitney U test). B: MSC-CM contained several neurotrophic 712 
proteins which were detected using custom designed antibody arrays. Arbitrary 713 
signal intensity readings were normalised to MSC number, data shown are from 714 
MSC-CM combined +/-SEM. C: MSC-CM was not sufficient stimiuli to promote 715 
neurite extension over inhibitory substrata of neurocan (top panels) or Nogo-A 716 
(bottom panels). Digitized images of identical fields are shown from left to right 717 
under phase contrast and fluorescence microscopy (middle panels illustrate the 718 
location of the neurocan or Nogo-A, right panels show NF immunolabelled 719 
neuronal bodies and neurites, calibration bars = 100m). There was no 720 
difference in the frequency of neuronal bodies with neurites which had adhered to 721 
nitrocellulose or inhibitory neurocan or Nogo-A substrata in neuronal growth 722 
media compared MSC-CM. Data shown are from at least 5 separate cultures and 723 
5 separate images per culture combined +/-SEM. 724 
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